Close this search box.

Shake up at BIO, highlights from ASGCT, and new data in IPF and obesity: a BioCentury podcast

Details on a reorganization at the high-profile biopharma advocacy group

By Stephen Hansen, Director of Biopharma Intelligence 

May 20, 2024 11:48 PM UTC

New BIO CEO John Crowley is reorganizing BIO in a bid to reshape how the organization communicates and enhance its focus on patients, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. The shake up includes layoffs of 30 out of 160 of BIO’s staff, including several leadership positions, and will establish eight centers of excellence at the organization.

BioCentury’s editors also recap the 24th annual BioEquity Europe conference that was held in San Sebastian, Spain last week, as well as highlights from last week’s American Society of Gene and Cell Therapy (ASGCT) conference. According to Director of Biopharma Intelligence Lauren Martz, the ASGCT highlights include methods to get AAV gene therapies across the blood-brain barrier and a host of new applications for vectorized antibody therapies.

The editors also discuss impressive early data from Endeavor BioMedicines Inc. in idiopathic pulmonary fibrosis (IPF) and Phase Ib obesity data from Roche (SIX:ROG; OTCQX:RHHBY).

This episode of BioCentury This Week was sponsored by Nxera Pharma Co. Ltd. For information on opportunities to sponsor The BioCentury Show and the BioCentury This Week podcast, please email